STUDY OF THE SAFETY AND PHARMACOKINETIC PROFILES OF RECOMBINANT RHUMAB VEGF

RhuMAb VEGF是一种实验性的人源化单抗，由 使用重组DNA技术的基因技术。抗体是一种蛋白质 可以保护身体免受外来入侵者的侵袭，例如细菌和病毒。 RhuMAb VEGF是一种抗血管内皮生长因子的单抗 (血管内皮生长因子)，它存在于各种正常组织中，但 由大多数实体癌症(肿瘤)产生的过量物质 癌症，血管内皮生长因子促进血管生长，为人体带来营养 肿瘤细胞。在实验室研究中，大黄单抗血管内皮生长因子抑制生长 通过阻断血管内皮生长因子的作用，在动物身上发现了许多不同的癌症。

rhuMAb VEGF is an experimental humanized monoclonal antibody produced by Genentech using recombinant DNA technology. Antibodies are proteins that can protect the body from foreign invaders, such as bacteria and viruses. rhuMAb VEGF is a monoclonal antibody to vascular endothelial growth factor (VEGF), which is present in a wide variety of normal tissues but is produced in excess by most solid cancers (tumors)> In the setting of cancer, VEGF promotes the growth of blood vessels that bring nutrients to the tumor cells. In laboratory studies, rhuMAb VEGF inhibits the growth of many different cancers in animals by blocking the effects of VEGF.